Financial reports
20-F
2023 FY
Annual report (foreign)
18 Apr 24
20-F/A
2022 FY
Annual report (foreign) (amended)
5 May 23
20-F
2022 FY
Annual report (foreign)
28 Apr 23
20-F
2021 FY
Annual report (foreign)
26 Apr 22
20-F
2020 FY
Annual report (foreign)
30 Apr 21
20-F/A
2019 FY
Annual report (foreign) (amended)
17 Jun 20
20-F
2019 FY
Annual report (foreign)
15 Jun 20
20-F/A
2018 FY
Annual report (foreign) (amended)
28 May 19
20-F
2018 FY
Annual report (foreign)
30 Apr 19
20-F
2017 FY
Annual report (foreign)
24 Apr 18
Current reports
6-K
Preliminary Results for the Year Ended 31 December 2023
19 Apr 24
6-K
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
23 Feb 24
6-K
Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024
22 Jan 24
6-K
Biodexa Appoints Ann Merchant to the Board of Directors
29 Dec 23
6-K
Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering
21 Dec 23
6-K
Current report (foreign)
6 Dec 23
6-K
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
27 Nov 23
6-K
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma
3 Oct 23
6-K
Current report (foreign)
29 Sep 23
6-K
Current report (foreign)
24 Jul 23
Registration and prospectus
424B3
Prospectus supplement
28 Mar 24
F-1
Registration statement (foreign)
18 Mar 24
424B3
Prospectus supplement
28 Feb 24
424B3
Prospectus supplement
28 Feb 24
424B3
Prospectus supplement
28 Feb 24
D
$6.79 mm in equity / options / securities to be acquired, sold $6.79 mm, 1 investor
3 Jan 24
424B3
Prospectus supplement
26 Dec 23
424B3
Prospectus supplement
26 Dec 23
424B3
Prospectus supplement
26 Dec 23
424B4
Prospectus supplement with pricing info
20 Dec 23
Proxies
No filings
Other
EFFECT
Notice of effectiveness
28 Mar 24
EFFECT
Notice of effectiveness
19 Dec 23
CORRESP
Correspondence with SEC
15 Dec 23
CORRESP
Correspondence with SEC
15 Dec 23
UPLOAD
Letter from SEC
12 Oct 23
EFFECT
Notice of effectiveness
29 Jun 23
EFFECT
Notice of effectiveness
27 Jun 23
CORRESP
Correspondence with SEC
23 Jun 23
UPLOAD
Letter from SEC
21 Jun 23
EFFECT
Notice of effectiveness
2 Jun 23
Ownership
SC 13G/A
Ionic Ventures, LLC
14 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
CVI Investments, Inc.
14 Feb 24
SC 13G/A
Cavalry Fund I LP
13 Feb 24
SC 13G
Bigger Capital, LLC
12 Feb 24
SC 13G
Mercer Street Global Opportunity Fund, LLC
8 Jan 24
SC 13G
Cavalry Fund I LP
28 Dec 23
SC 13G
Ionic Ventures, LLC
6 Mar 23
SC 13G
CVI Investments, Inc.
21 Feb 23
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 23